MDS Research Presented At The 15th Congress Of The European Hematology Association (EHA 2010)
The 15th Congress of the European Hematology Association (EHA) was held June 10 to 13 in Barcelona, Spain. Hematologists specializing in medicine and scientific research gathered to share developments in the field of hematology (blood and blood-related diseases).
Due to the broad number of interests and studies, the congress was divided into different sessions over the course of the four days. It included education sessions and workshops, poster sessions, and presentations about the latest hematologic studies and developments.
The congress featured numerous abstracts and presentations relating to myelodysplastic syndromes (MDS).
Many of the MDS presentations focused on the latest treatment developments. Several studies on Vidaza (azacitidine) were presented, including new information about effectiveness and tolerability in elderly patients and Vidaza’s use in patients with complex genetic abnormalities. Revlimid (lenalidomide) was evaluated for its impact on quality of life of patients who are red blood cell transfusion-dependent and have low- to intermediate-1 risk MDS.
Additional presentation topics included research on the relevance of genetic mutations in MDS diagnosis and progression, differences in protein levels in healthy individuals versus MDS patients, a proposal for a new scoring system for primary MDS, and studies on the impact of anemia on survival.
Over the next couple of weeks, The MDS Beacon will be covering some of the key findings.
More information on the congress can be found on the EHA website.
Related Articles:
- MDS Research To Be Presented At EHA Congress
- Latest MDS Research To Be Presented At The American Society Of Clinical Oncology’s 2010 Annual Meeting (ASCO 2010)
- Latest MDS Research To Be Presented At The 51st Meeting Of The American Society Of Hematology (ASH 2009)
- Latest MDS Research Findings To Be Presented At The American Society Of Hematology Annual Meeting (ASH 2011)
- Vidaza Treatment Effective And Safe In All Elderly MDS Patients (EHA 2010)
to whom it may concern:
i was diagnosed with MDS 4-5 years ago. threatment started with procrit, then aranesp and finally when revlidmid started 3 years ago i was one of the first in taking this med. i started with 10 mg once a day, now i take 5 mg once a day.
of course my white blood cells are at 2 and my platelets at 97, very low.
i am interested in any findings
thanks
Leave a comment